AGA. B. Gogolev

A. B. Gogolev

*This is an algorithmically generated author record based on publicly available information.

A. B. Gogolev has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    HER2-Ultralow in Invasive Breast Cancer: Frequency, Reclassification and Concordance of HER2 Status Assessment

    by Aktolkyn Kapsalim, Mariia Urezkova, Artem Gogolev

    Introduction. The expansion of indications for trastuzumab deruxtecan following the DESTINY-Breast06 trial has increased the clinical relevance of minimal HER2 membrane staining that was previously included within the HER2 0 category. In the current CAP protocol, HER2 0 is further subdivided into 0 with no membrane staining and 0+ with membrane staining, corresponding to the HER2-ultralow phenotype. Conventional HER2 immunohistochemistry (IHC) has historically been focused on identifying HER2 overexpression, whereas assessment of very low levels of HER2 staining is less reproducible. This places greater emphasis on the distinction between HER2 0 with no detectable expression (HER2-null), HER2-ultralow, and HER2 IHC 1+. Objective. To determine the frequency of HER2-ultralow expression among invasive breast carcinomas initially classified as HER2 0, to assess patterns of reclassification on repeat review, and to evaluate concordance between the initial and repeat standard HER2 status. Materials and Methods. A retrospective single-center study included 241 cases of invasive breast carcinoma without prior neoadjuvant therapy diagnosed between January and July 2026. Initial HER2 status was assessed by IHC in routine clinical practice according to the 2023 ASCO/CAP recommendations, and all slides were subsequently reviewed by a second pathologist. IHC was performed using the HER2 antibody clone 4B5 (Ventana). During repeat assessment, HER2 0 cases were further subclassified as HER2-null or HER2-ultralow. For concordance analysis, both subcategories were combined within the conventional HER2 0 category. Overall percent agreement and Cohen’s κ coefficient were calculated. Clinicopathological associations were evaluated in an exploratory analysis. Results. The initial HER2 distribution was as follows: 0 in 112/241 cases (46.5%), 1+ in 66 (27.4%), 2+ in 24 (10.0%), and 3+ in 39 (16.2%). Following repeat review, HER2-ultralow expression was identified in 55/241 cases (22.8%). Among the 112 tumors initially classified as HER2 0, 61 (54.5%) were categorized as HER2-null, 44 (39.3%; 95% CI, 30.7–48.5%) as HER2-ultralow, and 7 (6.2%) were reclassified as HER2 1+. Standard HER2 status changed in 22/241 cases (9.1%), with 20/22 discrepancies (90.9%) occurring at the HER2 0↔1+ boundary. Overall agreement was 90.9%, with a Cohen’s κ of 0.864. Among tumors initially classified as HER2 0 with known hormone receptor (HR) status, HER2-ultralow expression was identified in 35/80 (43.8%) HR-positive tumors and 2/16 (12.5%) HR-negative tumors (OR, 5.44; 95% CI, 1.16–25.55; p=0.024). No statistically significant differences were observed according to histologic grade or Ki-67 proliferation index. Discussion and Conclusions. HER2-ultralow expression was identified in 39.3% of tumors initially classified as HER2 0, a proportion comparable with that reported in recent retrospective studies. Changes in HER2 classification occurred predominantly at the HER2 0↔1+ boundary, highlighting the diagnostic vulnerability of the lower range of HER2 expression. Although concordance for conventional HER2 categories was high (κ=0.864), this analysis does not assess the reproducibility of distinguishing HER2-null from HER2-ultralow because interobserver agreement specifically at this boundary was not evaluated. These findings emphasize the heterogeneity of the HER2 0 category and support the importance of standardized assessment and explicit reporting of minimal HER2 membrane staining in routine pathologic practice.

  • Open Access

    PATTERNS OF DEVELOPMENT OF PATHOMORPHOLOGICAL TUMOR REGRESS AFTER NEOADJUVANT CHEMOTHERAPY FOR GASTRIC CANCER: EXPERIENCE OF THE NATIONAL RESEARCH ONCOLOGY CENTER

    by S.O. Bolsynbekova, A. Tuleubayeva, E.D. Ganieva, M.M. Urezkova, A.B. Gogolev, L.A. Pak

    Background: Gastric cancer remains one of the leading causes of cancer-related mortality worldwide. Perioperative neoadjuvant polychemotherapy (NAPCT) using the FLOT regimen has improved long-term outcomes; however, the prognostic value of pathological tumor regression grade (TRG) and its association with clinicopathological factors is not yet fully elucidated. Objective: To evaluate the association between tumor regression grade (TRG) assessed by the Mandard system, clinicopathological characteristics, and overall (OS) and relapse-free survival (RFS) in patients with locally advanced gastric cancer treated with NAPCT using the FLOT regimen. Materials and methods: A single-center retrospective cohort study was conducted, including 74 patients with stage II–III gastric adenocarcinoma treated with perioperative FLOT chemotherapy followed by surgery between 2020 and 2024. TRG was evaluated using the Mandard classification. Correlations were calculated using Spearman’s coefficient. Survival was analyzed by Kaplan–Meier method with log-rank test and univariate Cox regression. Statistical significance was set at p<0.05. Results: TRG was assessed in 70 resection specimens: TRG1 — 9 (12.9%), TRG2 — 2 (2.9%), TRG3 — 23 (32.9%), TRG4 — 10 (14.3%), TRG5 — 26 (37.1%). A clinically significant response (TRG1–2) was observed in 16% of patients. TRG showed significant correlation with ypT (ρ=0.51; p<0.001), ypN (ρ=0.36; p=0.0037), and the number of metastatic lymph nodes (ρ=0.36; p=0.0025). The presence of signet ring cells was associated with higher tumor grade (ρ=0.308; p=0.008) and ypT (ρ=0.324; p=0.007), but not with TRG. In univariate analysis, OS was significantly associated with ypN (ρ=–0.24; p=0.048) and the number of metastatic lymph nodes (ρ=–0.28; p=0.021). Median OS and RFS were not reached. Kaplan–Meier analysis demonstrated significantly better OS and RFS in responders (TRG1–2) compared to non-responders (log-rank χ²=7.9; p=0.005 and χ²=10.86; p=0.001, respectively). Conclusions: A strong pathological response after FLOT-based NAPCT is associated with improved survival; however, residual lymph node metastasis (ypN and number of involved nodes) remains the dominant prognostic factor. TRG should be interpreted in the context of nodal status. Further prospective multicenter studies with standardized pathological assessment are warranted to validate the independent prognostic role of TRG. Введение. Рак желудка остаётся одной из ведущих причин онкологической смертности в мире. Периоперационная неоадъювантная полихимиотерапия (НАПХТ) по схеме FLOT улучшает отдалённые результаты лечения, однако прогностическая значимость степени патоморфологического регресса опухоли (tumor regression grade, TRG) и её связь с клинико-патологическими характеристиками остаются недостаточно изученными. Цель исследования. Оценить взаимосвязь степени патоморфологического регресса по системе Mandard с клинико-патологическими параметрами, а также с показателями общей (ОВ) и безрецидивной выживаемости (БРВ) у пациентов с местнораспространённым раком желудка, получивших НАПХТ по схеме FLOT. Материалы и методы. Проведено одноцентровое ретроспективное когортное исследование, включающее 74 пациента с аденокарциномой желудка II–III стадии, получивших лечение по схеме FLOT и последующую хирургическую резекцию (2020–2024 гг.). Степень регресса оценивали по системе Mandard. Корреляции рассчитывали с использованием коэффициента Спирмена. Выживаемость оценивали методом Каплана–Майера с применением лог-рангового теста и однофакторного анализа регрессии Кокса. Статистическая значимость принималась при p<0,05. Результаты. TRG оценён у 70 пациентов: TRG1 — 9 (12,9%), TRG2 — 2 (2,9%), TRG3 — 23 (32,9%), TRG4 — 10 (14,3%), TRG5 — 26 (37,1%). Клинически значимый регресс (TRG1–2) наблюдался у 16% пациентов. Степень регресса достоверно коррелировала с остаточной стадией (ypT; ρ=0,51; p<0,001), статусом лимфоузлов (ypN; ρ=0,36; p=0,0037) и числом метастатически поражённых лимфоузлов (ρ=0,36; p=0,0025). Наличие перстневидноклеточного компонента ассоциировалось с более высоким грейдом опухоли (ρ=0,308; p=0,008) и большей стадией (ypT; ρ=0,324; p=0,007), однако не влияло на TRG. В однофакторном анализе на ОВ статистически значимо влияли ypN (ρ=–0,24; p=0,048) и число поражённых лимфоузлов (ρ=–0,28; p=0,021). Медианы ОВ и БРВ не были достигнуты. По данным анализа Каплана–Майера, пациенты с выраженным ответом (TRG1–2) имели лучшую ОВ и БРВ...

  • Changes in the WHO classification (2020) of soft tissue tumors

    by A.B. Gogolev, M.M. Urezkova, A.G. Kudaibergenova

    The article provides an overview of the main changes in the current (2020) WHO classification of soft tissue tumors, as well as selected updates that have occurred since the release of the classification.


  • Open Access

    Pelvic endoprosthesis in tumor lesions: experience of N.N. Petrov National Medical Research Center of Oncology

    by G. I. Gafton, Y. V. Gudz, Г. В. Зиновьев, M. A. Ebert, I. G. Gafton, M. S. Sinyachkin, A. V. Borodulin, A. B. Gogolev

    Introduction. Oncological endoprosthesis for tumors of the pelvic bones is rare. It is associated with certain difficulties and is insufficiently investigated.The study objective is to evaluate the results of surgical treatment of patients with tumors of the pelvis performed between 2012 and 2021 at the N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia.Materials and methods. The study included 23 patients with primary and secondary tumors of the pelvic bones who underwent limb-saving surgeries with substitution of the postresection defect with an endoprosthesis between 2012 and 2021. Mean follow-up duration was 19 months.Results. The most common postoperative complication was infection of the postoperative wound (n = 8; 35 %). Mechanical complications associated with the installed metallic prosthesis were observed in 4 (17 %) patients. Function al results were evaluated after 6 months using the Musculoskeletal Tumor Society Score (MSTS). Mean score per this scale was 53 % which corresponds to satisfactory outcome.Conclusion. Patients with malignant tumors of the pelvic bones should undergo treatment only in specialized medical facilities. Patients for organ-saving therapy should be carefully selected.


  • Open Access

    COLORECTAL CANCER DIAGNOSTICS VIA DETECTION OF TISSUE-SPECIFIC EXTRACELLULAR NANO-VESICLES

    by I. V. Nazarova, N. S. Nikiforova, E. I. Sidina, M. A. Slyusarenko, Z. S. Kotova, T. Yu. Semiglazova, M. A. Sluzhev, V. V. Semiglazov, A. B. Gogolev, A. S. Artemyeva, et al.

    ВОЗМОЖНОСТИ ДИАГНОСТИКИ КОЛОРЕКТАЛЬНОГО РАКА С ПОМОЩЬЮ ДЕТЕКЦИИ ТКАНЕ-СПЕЦИФИЧНЫХ ВНЕКЛЕТОЧНЫХ НАНО-ВАЗИКУЛ